A comparative study of the iron-clearing properties of subcutaneously administered desferrioxamine B (DFO) with those of orally administered desferrithiocin sodium salt (1 ), desmethyl desferrithiocin (2). desazadesmethyl desferrithiocin sodium salt (3), desazadesmethyl desferrithiocin pivaloyloxymethyl ester (4). and desazadesmethyl-5.5-dimethyl desferrithiocin (5) in an iron-loaded Cebus monkey model and a non-iron overloaded bile duct-cannulated rat model is presented. All six drugs, which performed well in rodent studies, demonstrated increased efficiency in the LTHOUGH considerable effort has been invested in the A development of new therapeutics for managing ironoverload diseases, the treatment has remained essentially unchanged. Patients with primary hemochromatosis are still treated by frequent phlebotomy, whereas patients suffering from iron overload secondary to blood transfusions, eg, Cooley's anemia, must be maintained on chelation therapy. Subcutaneous infusion of desfemoxamine B, a hexacoordinate hydroxamate iron chelator produced by Streptomyces pilosus,' is still regarded as the method of choice for treating transfusional iron
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Although the drug's efficacy and long-term tolerability are well documented, many individuals must be maintained on this regimen for most of their natural lives, and patient compliance can become a major problem. Furthermore, the cost of desferrioxamine treatment renders the population in areas with the greatest need untreatable. In principle, both of these difficulties would be overcome with a n orally effective iron chelator. 6 In recent years, several families of orally effective iron chelators have been identified; eg, pyridoxal isonicotinoyl hydrazones (PIHs), hydroxypyridones (CP20, CP94), and the desfemthiocins. Of these compounds, none has yet been shown to be completely satisfactory: All of these ligands have been associated with either low iron-clearing efficiency, toxic side effects, or both. Although its level of chronic toxicity is unacceptable, desferrithiocin has been shown to be a highly effective ligand at clearing iron from rodents and primates when administered
In the hopes of identifying those structural components of the molecule responsible for its deleterious effects, the chronic toxicities of desfemthiocin and four of its analogues were evaluated in rodents. In ad-0 1993 by The American Society of Hematology.
dition, the iron-clearing properties of these same molecules were measured in a non-iron-loaded bile duct-cannulated rat model and in an iron-overloaded Cebus monkey model. These studies revealed desmethyl desferrithiocin to be an orally effective iron chelator with minimal toxic side effects relative to the parent compound. It was determined that small structural alterations in the desfemthiocin backbone resulted in profound effects on the compound's toxicity while maintaining its iron clearing properties.
Although many chelators that are effective at removing iron in cell culture models" have been promoted to the next level of evaluation, the rodent model," many of the compounds that appeared outstanding in both of these screens have failed at the clinical level. Because of the many similarities of the iron-overloaded Cebus monkey*," to humans, it serves as an excellent intermediate screen for evaluating iron chelators before human studies. The results from this primate study suggest that selected desfemthiocins should now be considered for clinical evaluations.
MATERIALS AND METHODS
Materials. DFO (desfenioxamine B mesylate salt, trade name: Desferal) and the desfemthiocin analogues I through 5 were supplied by Ciba-Geigy Ltd (Basel, Switzerland). Cebus apella monkeys were purchased from World Wide Primates (Miami, FL). All reagents and standard iron solutions were obtained from Aldrich Chemical Co (Milwaukee, WI). Atomic absorption measurements were made on a Perkin-Elmer model 5100 PC (Nonvalk, CT). Ultrapure salts were obtained from Johnson Matthey Electronics (Royston, UK). Imferon, an iron dextran solution, was obtained from Fisons (Bedford, MA). Nalgene metabolic cages, rat jackets, and fluid swivels were purchased from Harvard Bioscience (South Natick, MA). lntramedic polyethylene tubing was obtained from Fisher Scientific (Pittsburgh, PA). All hematologic and serum chemical tests were camed out by Allied Clinical Laboratories (Gainesville, FL). Cremophor RH-40 was obtained from BASF (Parsippany, NJ), and Multistix 10 SG reagent strips for urinalysis were obtained from Miles Inc, Diagnostics Division (Elkhart, IN).
Desfemoxamine, desferrithiocin, and the desfemthiocin analogues were administered to the rats at 150 pmol/kg. Desfemoxamine was administered to the monkeys subcutaneously in sterile water for injection at 150 pmol/kg. Desfemthiocin itself was administered orally at a dose of 150 pmol/ kg, whereas the desfemthiocin analogues were given at 300 fimol/ kg. The reason for the differences in concentration was simply that we were already aware of an effective desfemthiocin dosage in primates, whereas this was not true for the analogues. In the initial Drug preparation and administration.
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measurements, we tested the compounds for their iron-clearing properties. The ligands were given by gavage in a 40% (vol/vol) solution of Cremophor RH-40/water using a No. 8 French infant feding tube. Before chelator administration, the monkeys were anesthetized with ketamine, 7 to 10 mg/kg, given intramuscularly (IM). In addition, the monkeys receiving the drugs orally were also given Reglan, 2.5 to 5 mg intravenously (IV) to prevent vomiting. Both the rats and the monkeys were fasted for 24 hours before dosing.
To further evaluate the iron-clearing properties of analogue 2, a dose-response study was performed in the primates. The compound was given orally at 150,300, and 450 pmollkg. At the 150-and 300-pmol/kg dosages, the drug was administered in a 40% (vol/vol) Cremophor/water solution. At the 450-pmollkg dose, to more closely mimic potential clinical applications in humans, the compound was administered in gelatin capsules.
A low-iron liquid diet was prepared by first mixing casein, 180 g; sucrose, 194 g; dextrin, 194 g; dextrose, 194 g; cellulose fiber, 90 g; vitamin mix, 5 g; methionine, 5 g; flavoring, 2 g; choline chloride, 2 g; and cholesterol, I g. The following liquids were then added to this mixture with stimng: corn oil, 45 g; coconut oil, 45 g; and soy lecithin, 20 g. Finally, the ultrapure salts (sodium chloride, 5.68 g; manganese sulfate, 0.04 g; calcium carbonate, 10.16 g; potassium dihydrogen phosphate, 1 1.93 g; and magnesium sulfate, 3.45 g) were added to 1,350 mL of distilled deionized water and combined with the nutrient mixture to prepare the final diet. Iron concentrations were determined for each batch of the food.
Animals were maintained on the low-iron liquid diet for 7 days before drug administration. The animals were given food according to their body weight, and intake was carefully monitored.
Three days before drug administration (day -2 to day 0), baseline iron intake and output values were measured. These same measurements were made for day + I through day +3. Iron-balance status was determined by subtracting the iron output from the iron input.
Seven days before the administration of the drug, the animals were placed in metabolic cages" and started on the low-iron liquid diet. Blood samples were taken for testing at this time. The blood samples were always drawn at the same time of day because of the diurnal variability in some of the measurements; eg, unsaturated iron-binding capacity (UIBC), plasma iron. The assays performed included iron profile (iron, UIBC, total iron-binding capacity [ , total cholesterol, total bilirubin, globulin, gamma-glutamyl transpeptidase). The evaluation of these parameters allowed us to assess the health of the animals going into the experiment and to measure changes that the test drug may induce in an animal. Any animals showing values outside of control were immediately removed from the experiment. Finally, a postdrug blood sample was taken from each animal on the last day of the experiment.
Twenty-four-hour fecal and urine collections began 4 days before the administration of the test drug. Fecal samples were assayed for the presence of occult blood, weighed and mixed with distilled deionized water, and autoclaved. The mixture was then homogenized, freeze-dried, and an aliquot of the resulting sample mixed with (65%) low-iron nitric acid and refluxed for 48 hours. Monkey urine samples were sterilized, acidified, Dose-response studies with analogue 2 in primates.
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The efficiency of each ligand was calculated assuming a 1 : 1 desfemoxamine-iron complex or a 2: 1 ligandiron complex for desfemthiocin and its analogues. In the monkeys, the efficiencies were generated by averaging the iron output for 4 days before the administration of the drug, subtracting this baseline from the 2-day iron clearance after the administration of the drug, and then dividing by the theoretical output. The efficiencies in the rodent model were calculated by subtracting the iron excretion of control animals from the iron excretion of the treated animals. This number was then divided by the theoretical output to obtain the efficiency. In this study, iron output is reported as micrograms of iron excreted per kilogram of animal weight.
Male SpragueDawley rats, averaging 400 g, were housed in Nalgene plastic metabolic cages during the experimental period and were given free access to water. The animals were anesthetized using sodium pentobarbital (50 mg/kg) given intraperitoneally (IP). The bile duct was cannulated using 22-gauge polyethylene tubing about 1 cm from the duodenum. The cannula was inserted about 2 cm into the duct, and once bile flow was established, the cannula was tied snugly in place. A skintunneling needle was inserted from the shoulder area around to the abdominal incision. The cannula was threaded through the needle until it emerged from the shoulder opening.
The cannula was then passed from the rat to the swivel inside a metal torque-transmitting tether, which was attached to a rodent jacket around the animal's chest. The cannula was directed from the rat to a Gilson micro fraction collector by a fluid swivel mounted above the metabolic cage. This system allowed the animal to move freely in the cage while continuous bile samples were being collected. Bile samples were collected at 3-hour intervals. Urine samples were taken every 24 hours. Sample collection and handling are as previously Male Sprague-Dawley rats, averaging 400 g, were housed in individual metabolic cages and fasted overnight. Before the first drug administration, the rats were weighed and evaluated for their general condition and a base-line urine sample was obtained for comparative purposes. The rats were given the drugs once daily for 10 days following an overnight fast. The compounds were administered at 384 pmol/kg and given by gavage in a 40%
Cremophor/water solution. The rats were fed 3 hours after drug administration and were allowed access to food for 5 hours. The amount of food and water consumed and the volume of urine produced were recorded each day. The urine samples were analyzed each morning by dip-stick (Multistix 10 SG) for the presence of white blood cells, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketones, bilirubin, and glucose. In addition, the animals were weighed and their activity level and general condition were noted each day before the administration of the drug. A necropsy was performed whenever an animal died or at the conclusion of the experiment. Control animals were given an equivalent amount of the Cremophor/water solution and were maintained on the same diet schedule as the test animals.
In addition, an experiment was carried out with all of the chelators clearing an equivalent amount of iron. In this case, the chelators were administered at 192 pmollkg (compounds 3,4, and 5 ) or 384 pmol/ kg (compounds 1 and 2), and the same experimental protocol was followed.
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RESULTS
A 1 O-day toxicity study was canied out o n compound 1 as well as on four of its analogues. A t the dosage investigated, compound 1 appeared to be highly nephrotoxic. Urinalysis indicated a drug that induced several
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disorders: glucosuria, persistent proteinuria, decreased urinary pH, and cessation of urine production. Necropsy revealed discoloration of the kidneys with areas of necrosis further attesting to renal impairment. In addition, tremors and ataxia were noted in all of the dying animals. All of the animals in this study were dead by day f5.
Although compound 1 was found to be nephrotoxic, analogues 3, 4, and 5 were found to be severe gastrointestinal irritants. At necropsy, the animals' GI tracts were hemorrhagic. The stomachs of all of the animals were grossly distended with gas and fluid. The stomach walls were paper thin and translucent; obvious musculature was noted only at the esophageal and duodenal junctures. In addition to the observed GI toxicity, several of the animals also had slight to profuse purulent ocular and/or nasal discharges indicating a systemic infection, which was further supported by the presence of white blood cells in the animals' urine samples, as well as a "left shift" when a peripheral blood smear was performed. Although some of the urinalysis findings, ie, glucosuria and proteinuria, may be associated with renal failure, at necropsy, the animals' kidneys did not display any obvious macroscopic lesions, and the condition of the GI tracts in these animals is suggestive of glucosuria secondary to acute pan~reatitis'~ and not due to renal failure. Finally, all ofthese animals were dead by day +6.
When compound 2 was evaluated using the same experimental protocol, no significant toxic side effects were found. All of the rodents survived the 10-day exposure to the drug. The animals ate well and had normal urine and fecal production throughout the experiment. In addition, a peripheral blood smear was performed that was comparable to that obtained from control animals. Postmortem examination and kidney histology revealed no significant abnormalities. This compound has emerged as the most promising analogue tested to date.
In addition to the above study, an experiment was performed in which all of the animals were given the compounds at a dosage at which the total iron excretion was equivalent. To determine the iron clearance, the compounds were first tested in the non-iron-overloaded bile duct-cannulated rats. It was determined that when compounds 3, 4, and 5 were administered at I92 pmol/kg, their iron clearance was 295 k 60, 33 1 k 23, and 376 f 6 I pg/kg, respectively, and when compounds 1 and 2 were given at 384 pmol/kg, their iron clearance was 308 t 56 and 278 f 44 pg/kg, respectively. A IO-day toxicity study was then performed as before. Once again, all of the rats except for those given compound 2 died. Necropsy results were essentially the same as those observed previously. This suggests that the toxicity of the desferrithiocins does not correlate with their ability to remove iron.
For all treated and untreated animals, complete blood counts (CBC) and kidney and liver profiles fell within the accepted normal range of the human values. Monkey fenitin could not be determined using the commercially available human ferritin antibody assay. The animals were alert, active, ate well, and had normal urine and feces production both before and after drug administration. However, it must be emphasized that this was a single
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dosage and that none of the monkeys were exposed to the drugs chronically.
Comparison of chelator-induced iron clearance in primates and rodents. Six iron chelators (Fig 1) were evaluated: desfemoxamine B (DFO) administered subcutaneously, desferrithiocin sodium salt (I), desmethyl desfemthiocin (2), desazadesmethyl desfenithiocin sodium salt (3), desazadesmethyl desfemthiocin pivaloyloxymethyl ester (4), and desazadesmethyl-5,5-dimethyl desfemthiocin (5) administered orally. The efficiency of orally administered desfemthiocin and its analogues was compared with subcutaneously administered DFO as a positive control. The efficiencies of the drugs were calculated based on the assumption that desferrioxamine forms a 1:l complex with iron and that the desfemthiocin analogues form a 2:l complex with the metal. The Cebus monkeys responded differently to the ligands than did the rats. Although the variability in ligand-induced iron clearance was higher in the monkeys than in the rats, with each primate serving as its own control, effective chelators were easily identified (Figs 2 and 3 ; Tables I and 2 ). The order of efficiency in the monkey model was 5
In previous st~dies,','~ we demonstrated that the efficiency of DFO dosed at 150 pmol/kg increased from 2.8% f 0.7% in the rats to 5.5% -t 0.9% (range 4.4% to 6.6%), in the iron overloaded primates (P < .001), whereas the efficiency of compound 1, also administered at 150 pmol/kg, increased from 2.5% f 1.2% in the rodent to 18.6% k 9.3% (range 10.3% to 33.9%) in the primates (P < .005). The mode of excretion for both ligands was different in the monkeys, with a larger percentage of iron being excreted in the urine than was observed in the rats.
Analogue 4 was approximately 2.7 times more efficient in the primates than it was in the rats, 8.4% f 3.9% (range, 4.5% to 12.9%) in the monkeys versus 3.1% * 1.8% in the rodents (P < .03), and it was as efficient as DFO given subcutaneously (P > .15). The mode of excretion was similar in both animal models, with the majority of the iron being excreted in the bile/feces; 94% in the rats and 67% in the monkeys. The efficiency of analogue 5 was also higher in the monkeys than it was in the rats, 6.7% f 1.8% in the rodent and 21.9% k 3.4% (range, 18.6% to 25.8%) in the primates (P < .001), and, in the primates, was found to be nearly 4 times as efficient as DFO given subcutaneously (P < .001). Once again, the majority of the induced iron was excreted in the bile/feces; 100% in the rodents and 89% in the primates. Although the efficiency of ligand 3 was higher in the monkeys than it was in the rats, 4.2% * 1.6% in the rodents versus 8.2% k 3.2% (range, 4.7% to 13.3%) in the primates (P < .04), the distribution of cleared iron was similar to that seen in the rat.' In the monkeys, 20% of the iron was excreted in the urine and 80% was excreted in the feces, whereas in the rodent, 4% of the iron was excreted in the urine and 96% was excreted in the bile. In the primates, this ligand was also found to be as efficient as DFO (P > . 1 1) . Finally, the efficiency of ligand 2 was also greater in the primates than in the rodents: 8.0% * 2.5% (range, 4.4% to 10.4%) in the primates versus 2.4% f 0.6% (range, 1.4% to 2.9%) in the rats (P < .001) and was as efficient as DFO (P > .07). In the monkeys, 42% of the iron was excreted in the stool and 58% in the urine, whereas in the rats, 82% of the iron was excreted in the bile and 18% in the urine.
To further evaluate the iron-clearing properties of analogue 2, a doseresponse study in the primates was performed. When the compound was administered orally at 150 @mollkg in 40% Cremophor, it was found to have an efficiency of 4.8% f 2.7%. Approximately 52% of the induced iron was excreted in the urine and 48% was excreted in the feces. At 300 @mol/kg, also administered orally in 40% Cremophor, the Dose-response studies with analogue 2. efficiency was 8.0% f 2.5%. Again, the iron excretion was nearly equally distributed between the urine and the feces; 58% in the urine and 42% in the feces. Finally, to more closely mimic potential clinical applications in humans, the compound was administered in gelatin capsules at 450 pmollkg. At this dose, the efficiency was 10.8% f 3.2%. However, this time the majority of the iron (86%) was excreted in the stool, with only 14% excreted in the urine. This shift in iron distribution may well be associated with the Cremophor vehicle. Although the efficiencies are close to within experimental error of each other, there is a def- inite dose response; the iron output increases almost linearly with chelator dose ( Table 3) .
Primate iron balance studies. It is critical to point out that in each experiment, the level of iron in the food was measured with atomic absorption spectroscopy. It was clear from these data that the animals absorb rather substantial amounts of iron under normal circumstances. In previous experiments,I3 it was demonstrated that DFO can hold the monkeys in negative iron balance. In the current study, compound 1 administered at I50 pmollkg and compound 2 administered at 150, 300, and 450 pmol/kg were also able to hold the monkeys in negative iron balance ( Table 3) . Primates in negative iron balance put out more iron than they absorb. Iron balance studies were not camed out on analogue 3, 4, or 5. At the time that these three analogues were being investigated, the conventional wisdom held that the desfemthiocins were uniformly toxic and it seemed that the results from an iron balance study would be a moot point. However, the rodent toxicity studies compelled us to reevaluate compounds 1 and 2.
DISCUSSION
The more highly alkylated compounds were consistently shown to be more effective as oral iron chelators in the primate model when comparing the relative activities among the desfemthiocins and the desazadesferrithiocins. For the desfemthiocins, the order was 1 > 2, whereas for the desazadesfemthiocins, the order was 5 > 4 > 3. In the case of the desazadesfemthiocins, we are assuming, of course, that the pivaloyloxy ester of compound 4 was cleaved by the nonspecific serum esterases to compound 3. This assumption is in keeping with the fact that on a molar basis the efficiencies of compounds 3 and 4 are essentially identical: 8.2% k 3.2% Venus 8.4% f 3.9% in the primates (P > .95) and 4.2% * 1.6% versus 3.1% k 1.8% in the rodents (P > .34). With this family of compounds, the non-iron-overloaded bile ductcannulated rat forecast the behavior of the ligands in the primates. Although there were quantitative differences (the chelators were more efficient in the primates), the order of effectiveness was essentially the same in both animal models.
There were also clear trends regarding the compounds' toxicities. Desferrithiocin was primarily nephrotoxic, whereas the major toxicity associated with the desaza compounds was GI toxicity. Because of their capacity to shut down ribonucleotide redu~tase,'~-'' it is somewhat surprising that more iron chelators do not present with GI toxicity. Intestinal epithelial cells are turning over so quickly that they are good targets for ribonucleotide reductase inhibitors. It would be interesting to determine if the IC5,, values of the chelators in cell culture could predict the toxicity of the chelators in animals. However, the fact that the least toxic desferrithiocin, analogue 2, was as efficient as analogues 3 and 4, suggests that the toxicity of the desfemthiocins does not weigh heavily on their ability to remove iron. Furthermore, it is certainly notable that the removal of the desfemthiocin aromatic nitrogen and the methyl group (compound 3) resulted in a shift from nephrotoxicity to GI toxicity, whereas the removal of the desfemthiocin methyl group (analogue 2) resulted in an analogue with substantially reduced toxic effects. The precise reason for the differences in toxicity among the various analogues of course still remains to be addressed. We are pursuing two approaches: a comparative study of the metabolic products and a comparative study of the clearance and organ distribution of the radiolabeled drugs. Nevertheless, the results from the primate study suggest that selected desfemthiocins should now be considered further as credible clinical targets. The amount of iron absorbed by the untreated animals over a 3-day period is compared with the amount of iron absorbed by the treated animals over a 3-day period. Net iron balance = dietary iron intake -(urinary iron + fecal iron). Animals in a negative iron balance are excreting more iron than they are absorbing.
However, it must be emphasized that further preclinical testing of analogue 2 involving long-term studies at a range of dosages as well as administration to a nonrodent species must be completed before its introduction into humans.
